Insulin Detemir (Levemir)
Insulin detemir (Levemir) is a long-acting basal analogue that binds albumin via a myristic-acid side chain to prolong action to ~12-20 hours. It is used off-label for basal nutrient partitioning; like all basal insulins its extended, irreversible action makes hypoglycaemia dangerous.
01 Overview
Detemir attaches a fatty-acid chain at B29 that reversibly binds albumin, buffering absorption and giving a smoother, more predictable basal profile than glargine at some doses. It is an approved basal insulin with a robust diabetes evidence base.
Some physique users choose detemir for a slightly shorter, more titratable basal window than glargine. It remains high-risk: the action cannot be recalled once injected, and hypoglycaemia can persist for many hours.
02 Mechanism
Activates the insulin receptor to drive glucose uptake and anabolic signalling; albumin binding via a fatty-acid chain slows absorption and buffers plasma levels for a prolonged basal effect.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Low (off-label) | 5–10 IU/day | SubQ | Long action; extreme caution |
| Diabetic basal | 10–40 IU/day | SubQ | Once or twice daily; individualised; medical use only |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Steady anabolic backdropProvides continuous low-level insulin supporting nutrient uptake. | Clinical | ||
| More predictable basal profileAlbumin buffering reduces day-to-day variability versus some basal insulins. | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Fat gainAdipose accrual from sustained insulin exposure; detemir tends to cause slightly less than other insulins. | Mild | Common | Clinical | |
| Prolonged hypoglycaemiaExtended, non-reversible action can drive lows over many hours, risking seizure, coma or death. | Life-threatening | Common in misuse | Clinical |